Relation of Race (Asian, African-American, European-American, and Hispanic) to Activated Clotting Time After Weight-Adjusted Bolus of Heparin During Percutaneous Coronary Intervention

Shimada, Yuichi J.; Nakra, Navin C.; Fox, John; Kanei, Yumiko

doi:10.1016/j.amjcard.2009.10.043

Cited by 21 publications

(17 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the vast majority of Japanese patients (92.5%) underwent diagnostic procedures, requiring a lower level of procedural anticoagulation, Asian patients may respond differently to unfractionated heparin. Indeed, Shimada et al have compared activated clotting times following initial administration of weight‐adjusted unfractionated heparin among different races of patients undergoing PCI . They found that Asian patients showed higher ACT compared to other racial groups, warranting reduced heparin dosage in this population.…”

Section: Discussionmentioning

confidence: 99%

Impact of sheath size and hemostasis time on radial artery patency after transradial coronary angiography and intervention in Japanese and non‐Japanese patients: A substudy from RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT) randomized multicenter trial

Aminian

Saïto

Takahashi

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of sheath size and hemostasis time on radial artery patency after transradial coronary angiography and intervention in Japanese and non‐Japanese patients: A substudy from RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT) randomized multicenter trial

Aminian

Saïto

Takahashi

et al. 2018

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Variations in the pharmacokinetic and pharmacodynamic properties of anticoagulants such as heparin and warfarin, as well as resulting clotting times, were observed among different racial groups, including different Asian ethnicities 8–10. For example, genetic polymorphism of cytochrome P450 (CYP) 2C9 as well as vitamin K epoxide reductase are both responsible for the lower warfarin maintenance doses among the three major Asian ethnic groups (Chinese, Malay, and Indian) 9,10.…”

Section: Introductionmentioning

confidence: 99%

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects

Chen¹,

Wang²,

Zhang³

et al. 2013

CPAA

View full text Add to dashboard Cite

BackgroundThe pharmacokinetics (PK), pharmacodynamics (PD), and safety of apixaban were assessed in healthy Chinese subjects in this randomized, placebo-controlled, double-blind, single-sequence, single- and multiple-dose study.Subjects and methodsEighteen subjects 18–45 years of age were randomly assigned (2:1 ratio) to receive apixaban or matched placebo. Subjects received a single 10 mg dose of apixaban or placebo on day 1, followed by 10 mg apixaban or placebo twice daily for 6 days (days 4–9). The PK and PD of apixaban were assessed by collecting plasma samples for 72 hours following the dose on day 1 and the morning dose on day 9, and measuring apixaban concentration and anti-Xa activity. Safety was assessed via physical examinations, vital sign measurements, electrocardiograms, and clinical laboratory evaluations.ResultsPK analysis showed similar characteristics of apixaban after single and multiple doses, including a median time to maximum concentration of ~3 hours, mean elimination half-life of ~11 hours, and renal clearance of ~1.2 L/hour. The accumulation index was 1.7, consistent with twice-daily dosing and the observed elimination half-life. Single-dose data predict multiple-dose PK, therefore apixaban PK are time-independent. The relationship between anti-Xa activity and plasma apixaban concentrations appears to be linear. Apixaban was safe and well tolerated, with no bleeding-related adverse events reported.ConclusionApixaban was safe and well tolerated in healthy Chinese subjects. Apixaban PK and PD were predictable and consistent with findings from previous studies in Asian and non-Asian subjects. The administration of apixaban does not require any dose modification based on race.

show abstract

“…Forth, in three of the four included studies patients were recruited in western countries, only the study Cassiopea involved Asian patients. As Asians were relatively at low risk of VTE [23] and required significantly less heparin to achieve the same goal of anticoagulation compared with other races [24] , the efficacy and safety of anticoagulants for Asian patients may be different from the western patients. Finally, there was significant heterogeneity in the efficacy analyses so we did not perform the meta-analyses.…”

Section: Discussionmentioning

confidence: 99%

Idraparinux or Idrabiotaparinux for Long-Term Venous Thromboembolism Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Song

Pavithra

et al. 2013

PLoS ONE

View full text Add to dashboard Cite

BackgroundVenous thromboembolism (VTE) is a prevalent disease with potential serious consequences. Idraparinux and idrabiotaparinux are two kinds of long-acting pentasaccharides. Evidence has shown that idraparinux and idrabiotaparinux are effective anticoagulants. However, up to now, there is no consensus on whether they are better than other anticoagulation methods for long-term VTE treatment.ObjectiveTo evaluate the effect of idraparinux or idrabiotaparinux versus other anticoagulation methods for long-term VTE treatment.MethodsWe searched Cochrane Central Register of Controlled Trials, PubMed, Embase, Web of science, clinical trial registry web sites (clinical trials,WHO clinical trial registry), Googlescholar, PubMed related articles and companies' web sites electronically up to Dec 30th, 2012 and manually searched the reference lists and conference proceedings. Only randomized controlled trial (RCT) involving adult patients comparing idraparinux and/or idrabiotaparinux versus other anticoagulation methods for long-term VTE treatment was included. Two reviewers evaluated the studies and extracted data independently. Pooled risk ratios (RRs) were calculated as outcome measures and Revman 5.2 software was used to analyze data. Our primary efficacy and safety outcomes were the recurrent VTE and major bleeding rates.ResultsWe included four RCTs and involved 8584 participants on idraparinux or idrabiotaparinux versus standard warfarin for VTE treatment from 9364 references. We did not perform meta-analysis on the VTE rate because of the significant heterogeneity. We used the fixed effect model to analyze the safety outcomes and demonstrated that idraparinux or idrabiotaparinux decreased major bleeding rate significantly (RR 0.73, 95% CI 0.54 to 0.98, P = 0.04) but had a trend to increase the all cause mortality (RR 1.26, 95% CI 1.00 to 1.57, P = 0.05) compared with warfarin.ConclusionsUntil now there is not sufficient evidence to clarify whether idraparinux or idrabiotaparinux is as effective and safe as the standard warfarin treatment for VTE treatment.

show abstract

Relation of Race (Asian, African-American, European-American, and Hispanic) to Activated Clotting Time After Weight-Adjusted Bolus of Heparin During Percutaneous Coronary Intervention

Cited by 21 publications

References 3 publications

Impact of sheath size and hemostasis time on radial artery patency after transradial coronary angiography and intervention in Japanese and non‐Japanese patients: A substudy from RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT) randomized multicenter trial

Impact of sheath size and hemostasis time on radial artery patency after transradial coronary angiography and intervention in Japanese and non‐Japanese patients: A substudy from RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT) randomized multicenter trial

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects

Idraparinux or Idrabiotaparinux for Long-Term Venous Thromboembolism Treatment: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About